Skip to main content

Day: February 4, 2022

HeartFlow Announces Mutual Termination of Business Combination Agreement

REDWOOD CITY, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) — HeartFlow Holding, Inc. (“HeartFlow”), the leader in revolutionizing precision heart care, today announced that it and Longview Acquisition Corporation II (NYSE: LGV), a special purpose acquisition company sponsored by affiliates of Glenview Capital Management, LLC, have mutually agreed to terminate their previously announced business combination agreement, effective immediately, as a result of current unfavorable market conditions.  About HeartFlowHeartFlow is the leader in revolutionizing precision heart care, uniquely combining human ingenuity with advanced technology. HeartFlow’s non-invasive HeartFlow FFRct Analysis leverages artificial intelligence to create a personalized three-dimensional model of the heart. Clinicians can use this model to evaluate the impact a blockage...

Continue reading

Update from Special Committee of Pilgrim’s Pride

GREELEY, Colo., Feb. 04, 2022 (GLOBE NEWSWIRE) — The Special Committee of the Board of Directors of Pilgrim’s Pride Corporation (NASDAQ: PPC) today provided an update to the full Board of Directors of Pilgrim’s Pride on the status of discussions with JBS S.A. regarding JBS’s unsolicited proposal to acquire all of the outstanding shares of common stock of Pilgrim’s Pride that JBS does not currently own for $26.50 per share in cash, which was previously announced on August 13, 2021. The Special Committee has carefully and thoroughly reviewed the proposal from JBS in consultation with its financial and legal advisors. On October 29, 2021, the Special Committee informed JBS that it would not support the JBS proposal unless JBS significantly increased its purchase price. On November 15, 2021, JBS offered to increase...

Continue reading

Osisko Metals Grants Stock Options

MONTREAL, Feb. 04, 2022 (GLOBE NEWSWIRE) — Osisko Metals Incorporated (the “Company” or “Osisko Metals”) (TSX-V: OM; OTCQX: OMZNF; FRANKFURT: 0B51) announces that its Board of Directors approved the grant of incentive stock options to certain directors, officers, key employees and key consultants to purchase up to an aggregate of 685,000 common shares in the capital stock of the Company. Grants are subject to a three-year vesting period and a five-year term at an exercise price of $0.37 per share. About Osisko Metals Osisko Metals Incorporated is a Canadian exploration and development company creating value in the base metal space. The Company controls one of Canada’s premier past-producing zinc mining camps, the Pine Point Project, located in the Northwest Territories for which the 2020 PEA has indicated an after-tax NPV of $500M...

Continue reading

ION receives continued listing standard notice from the NYSE

HOUSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) — ION Geophysical Corporation (NYSE: IO) today announced that it received notice on January 31, 2022 from the New York Stock Exchange (the “NYSE”) that the price of its common stock fell below the NYSE’s continued listing standards. The NYSE requires that the average closing price of a listed company’s common stock remain above $1.00 per share over a consecutive 30 trading-day period. As of January 28, 2022, the 30 trading-day period average closing price of the Company’s common stock was $0.94 per share. In accordance with NYSE rules, the Company must notify the NYSE within 10 business days of receipt of the notification with its intent to cure the deficiency. The Company has six months to regain compliance with the NYSE continued listing requirements. During...

Continue reading

Baosheng Media Group Holdings Limited Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Beijing, China, Feb. 04, 2022 (GLOBE NEWSWIRE) — Baosheng Media Group Holdings Limited (NASDAQ: BAOS) (“Baosheng” or the “Company”), a China-based online marketing solution provider, today announced that the Company received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on February 1, 2022, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Rules for continued listing on the Nasdaq. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US$1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s ordinary...

Continue reading

Grayscale Investments® Amends Select Digital Asset Products’ Valuation Methodology

New York, Feb. 04, 2022 (GLOBE NEWSWIRE) — Grayscale Investments® (the “Sponsor”), the world’s largest digital currency asset manager, today announced that it has amended the methodology used to determine the Index Price of select Grayscale products (“the Select Products”).  This Index Price change will be applied to several single-asset Grayscale Trusts, including: Grayscale® Basic Attention Token Trust Grayscale® Bitcoin Trust Grayscale® Bitcoin Cash Trust Grayscale® Chainlink Trust Grayscale® DeFi Fund Grayscale® Digital Large Cap Fund Grayscale® Ethereum Trust Grayscale® Ethereum Classic Trust Grayscale® Litecoin Trust Grayscale® Solana Trust Grayscale® Stellar Lumens Trust Grayscale® Zcash TrustThe Select Products have historically valued their respective assets...

Continue reading

ObsEva Provides Update on EU Marketing Authorisation Process for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – February 4, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that based on ongoing communications with the European Medicines Agency (EMA), further questions on the marketing authorisation application for linzagolix may be forthcoming, thereby extending the application timeline. ObsEva is in dialogue with the EMA to understand areas that may require further clarification and is committed to promptly addressing any questions that could arise. In the United States, the New Drug Application for linzagolix for the treatment of uterine fibroids has been accepted for review by the United States Food and Drug Administration (FDA), with a PDUFA target...

Continue reading

PDC Energy Announces 2021 Fourth Quarter and Year-End Conference Call – Tuesday, March 1, 2022

DENVER, Feb. 04, 2022 (GLOBE NEWSWIRE) — PDC Energy, Inc. (“PDC” or the “Company”) (Nasdaq:PDCE) today announced plans to host a conference call to discuss fourth quarter and full-year 2021 operating and financial results. The Company plans to issue its news release after market close on Monday, February 28, followed thereafter by additional materials. The release and materials will be available on the Company’s website, www.pdce.com.Conference Call and Webcast:Date/Time: Tuesday, March 1, 2022 at 11:00 a.m. ETDomestic (toll free): 877-312-5520 International: 1-253-237-1142 Conference ID: 2197232Webcast: available at www.pdce.com Replay Information:Domestic (toll free): 855-859-2056 International: 1-404-537-3406 Conference ID: 2197232Webcast Replay: available for six months at www.pdce.comAbout PDC Energy, Inc. PDC Energy,...

Continue reading

Apollo Tactical Income Fund Inc. Declares February 2022 Monthly Distribution of $0.085 Per Share

NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) — (NYSE: AIF) – Apollo Tactical Income Fund Inc. (the “Fund”) today announced the declaration of its distribution for the month of February 2022 of $0.085 per common share, payable on the date noted below. The following dates apply to the declared distribution: Ex-Date: February 16, 2022 Record Date: February 17, 2022 Payment Date: February 28, 2022 Per Share Amount: $0.085 Apollo Contact Information: Product Literature 877-864-4834 Investors Elizabeth Besen Investor Relations Manager Apollo Global Management, Inc. 212-822-0625 ebesen@apollo.com Forward-Looking Statements This press release may contain statements that are forward looking, as that term is defined by the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules,...

Continue reading

Apollo Senior Floating Rate Fund Inc. Declares February 2022 Monthly Distribution of $0.080 Per Share

NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) — (NYSE: AFT) – Apollo Senior Floating Rate Fund Inc. (the “Fund”) today announced the declaration of its distribution for the month of February 2022 of $0.080 per common share, payable on the date noted below. The following dates apply to the declared distribution: Ex-Date: February 16, 2022 Record Date: February 17, 2022 Payment Date: February 28, 2022Per Share Amount: $0.080 Apollo Contact Information: Product Literature 877-864-4834 Investors Elizabeth Besen Investor Relations ManagerApollo Global Management, Inc.212-822-0625 ebesen@apollo.com Forward-Looking Statements This press release may contain statements that are forward looking, as that term is defined by the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission in its rules,...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.